Skip Navigation

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing

Loading video...

1,071 Views

Air date: Wednesday, June 24, 2020, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 1,071 (641 Live, 430 On-demand)
Category: COVID-19
Runtime: 00:55:49
Description: NIH COVID-19 SIG Lecture Series

Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This webinar will describe Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity–purification mass spectrometry to identify the human proteins physically associated with each. Among 332 high–confidence SARS-CoV-2-human protein–protein interactions, Krogan's lab has identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, Krogan's lab has used several viral assays to identify two sets of pharmacological agents that displayed antiviral activity.
NLM Title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing / Nevan Krogan.
Author: Krogan, Nevan J.
National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract: (CIT): NIH COVID-19 SIG Lecture Series. Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This webinar will describe Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity-purification mass spectrometry to identify the human proteins physically associated with each. Among 332 high-confidence SARS-CoV-2-human protein-protein interactions, Krogan's lab has identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, Krogan's lab has used several viral assays to identify two sets of pharmacological agents that displayed antiviral activity.
Subjects: Betacoronavirus--drug effects
Drug Delivery Systems
Drug Repositioning
Protein Biosynthesis--drug effects
Protein Interaction Maps
Viral Nonstructural Proteins--drug effects
Publication Types: Lecture
Webcast
 
NLM Classification: QW 168.5.C8
NLM ID: 101769638
CIT Live ID: 37828
Permanent link: https://videocast.nih.gov/watch=37828

Related Videos...

Click Here to Play Video.
08:14:11
INCLUDE Project: Clinical Trials in Down Syndrome Workshop (Day 1)
[Conferences]
5/7/2020
Click Here to Play Video.
03:46:11
NCI Board of Scientific Advisors (BSA) - March 2023
[NCI Board of Scientific Advisors]
3/21/2023
Click Here to Play Video.
05:45:19
NIH Advisory Committee on Research on Women’s Health - April 2023
[Advisory Boards and Councils]
4/12/2023
Click Here to Play Video.
04:09:18
ICCVAM 2023 Public Forum Day (Day 2)
[Conferences]
5/19/2023
Click Here to Play Video.
06:04:17
Advances in Aging, Immunity and Chronic Inflammatory Diseases (Day 2)
[Conferences]
5/10/2023
Click Here to Play Video.
05:59:56
Advisory Committee to the Director - June 2023 (Day 1)
[Advisory Committee to the Director of the NIH]
6/8/2023
Click Here to Play Video.
HIV Structural Biology (Day 1)
[Conferences]
6/26/2023
Click Here to Play Video.
07:24:21
Maximizing NIH's Levers to Catalyze Technology Transfer
[Conferences]
7/31/2023
Click Here to Play Video.
05:50:42
Strategies for an HIV Cure (Day 1)
[Conferences]
10/12/2023
Click Here to Play Video.
06:26:12
ADVANCING ME/CFS RESEARCH: Identifying Targets for Intervention and Learning from Long COVID
[Conferences]
12/12/2023